scholarly journals Peripheral and total circulating extracellular vesicle levels of advanced glycation end‐products and RAGEs as possible biomarkers for mild cognitive impairment and Alzheimer's patients

2020 ◽  
Vol 16 (S4) ◽  
Author(s):  
Mohamed Haddad ◽  
Morgane Khedher ◽  
Mohamed Raâfet Ben Khedher ◽  
Tamas Fulop ◽  
Charles Ramassamy
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Advanced Glycation End Products ◽  
Extracellular Vesicle ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Levels of Receptor for Advanced Glycation End Products and Glyoxalase-1 in the Total Circulating Extracellular Vesicles from Mild Cognitive Impairment and Different Stages of Alzheimer’s Disease Patients

2021 ◽  
pp. 1-11
Author(s):  
Mohamed Haddad ◽  
Morgane Perrotte ◽  
Mohamed Raâfet Ben Khedher ◽  
Elise Madec ◽  
Aurelie Lepage ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Extracellular Vesicles ◽  
Advanced Glycation End Products ◽  
Neuronal Cells ◽  
Advanced Glycation ◽  
Glyoxalase 1 ◽  
Glycation End Products ◽  
End Products

Background: Growing evidence supports that receptor for advanced glycation end products (RAGE) and glyoxalase-1 (GLO-1) are implicated in the pathophysiology of Alzheimer’s disease (AD). Extracellular vesicles (EVs) are nanovesicles secreted by almost all cell types, contribute to cellular communication, and are implicated in AD pathology. Recently, EVs are considered as promising tools to identify reliable biomarkers in AD. Objective: The aim of our study was to determine the levels of RAGE and GLO-1 in circulating EVs from mild cognitive impairment (MCI) and AD patients and to analyze their correlation with the clinical Mini-Mental State Examination and Montreal Cognitive Assessment scores. We have studied the possibility that neuronal cells could release and transfer GLO-1 through EVs. Methods: RAGE and GLO-1 levels were measured in circulating EVs, respectively, by Luminex assay and western blot. Released-EVs from SK-N-SH neuronal cells were isolated and GLO-1 levels were determined by western bot. Results: Our data showed higher levels of RAGE in EVs from late AD patients while GLO-1 levels in EVs from early AD were lower as compared to control and MCI patients. Interestingly, levels of RAGE and GLO-1 in EVs were correlated with the cognitive scores regardless of age. For the first time, we demonstrated that GLO-1 was released from neuronal cells through EVs. Conclusion: Although more samples will be needed, our preliminary results support the use of peripheral EVs cargo as new tools for the discovery of peripheral AD biomarkers.

Effect of Advanced Glycation End Products on Cognition in Older Adults with Type 2 Diabetes: Results from a Pilot Clinical Trial

2021 ◽  
pp. 1-11
Author(s):  
Roni Lotan ◽  
Ithamar Ganmore ◽  
Abigail Livny ◽  
Nofar Itzhaki ◽  
Mark Waserman ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Older Adults ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Pilot Trial ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Global Cognition

Background: Dietary advanced glycation end-products (AGEs) are linked to cognitive decline. However, clinical trials have not tested the effect of AGEs on cognition in older adults. Objective: The aim of the current pilot trial was to examine the feasibility of an intervention to reduce dietary AGEs on cognition and on cerebral blood flow (CBF). Methods: The design is a pilot randomized controlled trial of dietary AGEs reduction in older adults with type 2 diabetes. Seventy-five participants were randomized to two arms. The control arm received standard of care (SOC) guidelines for good glycemic control; the intervention arm, in addition to SOC guidelines, were instructed to reduce their dietary AGEs intake. Global cognition and CBF were assessed at baseline and after 6 months of intervention. Results: At baseline, we found a reverse association between AGEs and cognitive functioning, possibly reflecting the long-term toxicity of AGEs on the brain. There was a significant improvement in global cognition at 6 months in both the intervention and SOC groups which was more prominent in participants with mild cognitive impairment. We also found that at baseline, higher AGEs were associated with increased CBF in the left inferior parietal cortex; however, 6 months of the AGEs lowering intervention did not affect CBF levels, despite lowering AGEs exposure in blood. Conclusion: The current pilot trial focused on the feasibility and methodology of intervening through diet to reduce AGEs in older adults with type 2 diabetes. Our results suggest that participants with mild cognitive impairment may benefit from an intensive dietary intervention.

scholarly journals Receptor for advanced glycation end products mediates meningitis‐triggered amyloid‐β accumulation and cognitive impairment

2020 ◽  
Vol 16 (S3) ◽  
Author(s):  
Tatiana Barichello ◽  
Jaqueline S Generoso ◽  
Vijayasree V Giridharan ◽  
Allan Collodel ◽  
Diogo Dominguini ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Advanced Glycation End Products ◽  
Amyloid Β ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation, Tau phosphorylation, and cognitive impairment

2017 ◽  
Vol 293 (1) ◽  
pp. 226-244 ◽  
Author(s):  
Juciano Gasparotto ◽  
Carolina S. Girardi ◽  
Nauana Somensi ◽  
Camila T. Ribeiro ◽  
José C. F. Moreira ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Advanced Glycation End Products ◽  
Amyloid Β ◽  
Tau Phosphorylation ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products
Sign in / Sign up

Export Citation Format

Share Document